← All indications
Fibrosarcoma
A sarcoma derived from deep fibrous tissue, characterized by bundles of immature proliferating fibroblasts with variable collagen formation, which tends to invade locally and metastasize by the bloodstream. (Stedman, 25th ed)
Subtype terms (2)
More specific conditions that are subtypes of Fibrosarcoma in the MeSH hierarchy.
- Dermatofibrosarcoma
9 drugs (6 approved, 3 experimental)
- Neurofibrosarcoma
38 drugs (27 approved, 11 experimental)
Drugs by status
Phase 3 trials (3)
Phase 2 trials (32)
- saracatinib
- dexrazoxane
- sorafenib
- temsirolimus
- cixutumumab
- selinexor
- vismodegib
- gemcitabine
- paclitaxel
- imatinib
- nivolumab
- pembrolizumab
- larotrectinib
- alisertib
- olaratumab
- ipilimumab
- sunitinib
- reolysin
- ro4929097
- sapanisertib
- bevacizumab
- Selpercatinib
- masct:multiple antigens specific cellular therapy
- docetaxel
- romidepsin
- dactinomycin
- melphalan
- 9-ing-41
- tislelizumab
- BA3011
- +2 more
Phase 1 trials (4)
Organizations
Organization Involved with Phase 3 Indications (1)
Organization Involved with Phase 2 Indications (18)
- Celgene
- Pfizer
- Oncolytics Biotech
- National Institutes of Health (NIH)
- Cornell University
- Harvard University
- Eastern Cooperative Oncology Group
- Medical College of Wisconsin
- Oregon Health and Science University
- Southwest Oncology Group
- University of Miami
- University of South Florida
- University of Toronto
- Wake Forest University
- University of California, San Francisco
- Loxo Oncology
- Maria Sklodowska Curie Children's Hospital
- Washington University in St. Louis
Organization Involved with Phase 1 Indications (2)